Overbrook Management Corp Has $6.17 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Overbrook Management Corp lessened its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 26.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 219,677 shares of the biopharmaceutical company's stock after selling 79,035 shares during the period. Royalty Pharma comprises 1.2% of Overbrook Management Corp's investment portfolio, making the stock its 22nd largest holding. Overbrook Management Corp's holdings in Royalty Pharma were worth $6,171,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of RPRX. Allworth Financial LP raised its holdings in Royalty Pharma by 89.8% during the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 451 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Royalty Pharma by 112.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 531 shares during the period. Lindbrook Capital LLC raised its holdings in Royalty Pharma by 485.2% during the 4th quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 1,999 shares during the period. Rakuten Securities Inc. acquired a new stake in Royalty Pharma during the 4th quarter worth about $110,000. Finally, CWM LLC increased its holdings in shares of Royalty Pharma by 75.9% in the 3rd quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company's stock valued at $130,000 after purchasing an additional 2,064 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Up 0.5 %

NASDAQ:RPRX traded up $0.13 during mid-day trading on Thursday, reaching $28.11. The stock had a trading volume of 2,287,427 shares, compared to its average volume of 2,678,977. The business's 50 day moving average is $29.65 and its 200 day moving average is $28.54. Royalty Pharma plc has a fifty-two week low of $25.92 and a fifty-two week high of $35.76. The stock has a market cap of $16.79 billion, a P/E ratio of 14.87 and a beta of 0.45. The company has a debt-to-equity ratio of 0.61, a current ratio of 7.90 and a quick ratio of 7.90.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.03 by $0.12. The firm had revenue of $736.00 million during the quarter, compared to analysts' expectations of $702.90 million. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. As a group, sell-side analysts predict that Royalty Pharma plc will post 3.95 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be given a $0.21 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $0.84 annualized dividend and a dividend yield of 2.99%. Royalty Pharma's dividend payout ratio is 44.44%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RPRX. Bank of America dropped their target price on Royalty Pharma from $40.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, April 12th. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a report on Thursday, April 11th. JPMorgan Chase & Co. dropped their target price on Royalty Pharma from $45.00 to $42.00 and set an "overweight" rating on the stock in a report on Tuesday, February 20th. Finally, The Goldman Sachs Group dropped their target price on Royalty Pharma from $56.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, February 20th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $46.75.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.